EPZM News and Press, Epizyme Inc. From 05/10/22

Epizyme, Inc. (EPZM) Q1 2022 Earnings Conference Call May 10, 2022, 08:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal - Senior Medical Adviser, Interim Chief Medical and Development Officer Joe Beaulieu - Senior Vice President, Head of...

Epizyme press release (NASDAQ:EPZM): Q1 GAAP EPS of -$0.38 misses by $0.03. Revenue of $8.69M (+13.9% Y/Y) misses by $1.33M. Cash, cash equivalents and marketable securities were $199.7 million as of March 31, 2022, compared to $176.8 million as of December 31, 2021. For further details see...

TAZVERIK® (tazemetostat) Net Product Revenue of $ 8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme’...

Epizyme (NASDAQ:EPZM) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.35 (+49.3% Y/Y) and the consensus Revenue Estimate is $10.02M (+31.3% Y/Y). Over the last 1 year, EPZM has beaten EPS estimates 75% of the time and ha...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter ...

Epizyme (NASDAQ:EPZM) Chief Medical and Development Officer Shefali Agarwal has resigned from the company effective Wednesday. She will remain as a senior medical consultant, and in that role, also serve as acting chief medical and development officer. Year to date through Wednesday's cl...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced its participation in two investor conferences in March. Cowen 42nd Annual Health Care C...

The following slide deck was published by Epizyme, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Epizyme, Inc. 2021 Q4 - Results - Earnings Call Presentation

Epizyme, Inc. (EPZM) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal – Executive Vice President, Chief Medical and Development Officer Conference Call Participants Joseph Thome &#x...